77 related articles for article (PubMed ID: 19863180)
1. Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.
Lymphoma Research Foundation LRF
Oncology (Williston Park); 2024 Feb; 38(2):51-67. PubMed ID: 38421601
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological, clinical and therapeutic profiles of mantle cell lymphoma cared for in a Moroccan center: a review of 14 cases.
Abakarim O; Mansouri A; Hebbezni A; Boujguenna I; Lahlimi FE; Tazi I
Pan Afr Med J; 2024; 47():111. PubMed ID: 38828423
[TBL] [Abstract][Full Text] [Related]
3. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR; Li X; Liao LP; Han J; Huang J; Li JC; Tao HR; Fan SJ; Chen ZF; Li Q; Chen SJ; Ding H; Yang YX; Zhou B; Jiang HL; Chen KX; Zhang YY; Huang CX; Luo C
Acta Pharmacol Sin; 2022 Feb; 43(2):457-469. PubMed ID: 33850273
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous involvement as a rare first sign of systemic mantle cell lymphoma: A case report and review of the literature.
Hrgovic I; Hartmann S; Steffen B; Vogl T; Kaufmann R; Meissner M
Mol Clin Oncol; 2016 May; 4(5):728-732. PubMed ID: 27123271
[TBL] [Abstract][Full Text] [Related]
5. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous lesions as presentation form of mantle cell lymphoma.
Merino de Paz N; Rodríguez-Martín M; Contreras Ferrer P; García-Hernández S; Hernández-León N; Martín-Herrera A; Noda-Cabrera A
Dermatol Reports; 2011 Oct; 3(3):e51. PubMed ID: 25386303
[TBL] [Abstract][Full Text] [Related]
7. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
Chen Z; Pittman EF; Romaguera J; Fayad L; Wang M; Neelapu SS; McLaughlin P; Kwak L; McCarty N
PLoS One; 2013; 8(8):e69126. PubMed ID: 23936317
[TBL] [Abstract][Full Text] [Related]
8. Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
Kirschey S; Wagner S; Hess G
Clin Med Insights Oncol; 2012; 6():153-64. PubMed ID: 22550404
[TBL] [Abstract][Full Text] [Related]
9. Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE; Dybedal I; Holte H; Heldal D; Torfoss D; Aurlien E; Lauritzsen GF; Fosså A; Lehne G; Baggerød E; Kvalheim G; Egeland T; Bishop MR; Fowler DH; Kolstad A
Bone Marrow Transplant; 2012 Dec; 47(12):1552-7. PubMed ID: 22522568
[TBL] [Abstract][Full Text] [Related]
10. Primary mantle cell lymphoma of the trachea.
Guddati AK; Marak CP
Med Oncol; 2012 Dec; 29(4):2385-7. PubMed ID: 22392198
[TBL] [Abstract][Full Text] [Related]
11. Solitary primary gastric mantle cell lymphoma.
Kim CH; Chun HJ; Kim TH; Jung W; Kim S; Hyun JJ; Keum B; Seo YS; Kim YS; Jeen YT; Lee HS; Um SH; Kim CD; Ryu HS; Kim I
Gut Liver; 2011 Dec; 5(4):527-31. PubMed ID: 22195254
[TBL] [Abstract][Full Text] [Related]
12. Biopsy-proven mantle cell lymphoma in brain parenchyma.
Gurevitz SA; Goldfarb JM; Cooper B; Krause JR; Stone MJ
Proc (Bayl Univ Med Cent); 2011 Jan; 24(1):45-7. PubMed ID: 21307976
[TBL] [Abstract][Full Text] [Related]
13. Mantle cell lymphoma: state-of-the-art management and future perspective.
Weigert O; Unterhalt M; Hiddemann W; Dreyling M
Leuk Lymphoma; 2009 Dec; 50(12):1937-50. PubMed ID: 19863180
[TBL] [Abstract][Full Text] [Related]
14. Current treatment standards and emerging strategies in mantle cell lymphoma.
Dreyling M; Hiddemann W;
Hematology Am Soc Hematol Educ Program; 2009; ():542-51. PubMed ID: 20008239
[TBL] [Abstract][Full Text] [Related]
15. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
[TBL] [Abstract][Full Text] [Related]
16. Current management of mantle cell lymphoma.
Weigert O; Unterhalt M; Hiddemann W; Dreyling M
Drugs; 2007; 67(12):1689-702. PubMed ID: 17683170
[TBL] [Abstract][Full Text] [Related]
17. [Current treatment strategy in mantle cell lymphoma].
Ogura M
Nihon Rinsho; 2014 Mar; 72(3):499-511. PubMed ID: 24724411
[TBL] [Abstract][Full Text] [Related]
18. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Kluin-Nelemans HC; Beà S; Hartmann E; Salaverria I; Hutter G; Perez-Galan P; Roue G; Pott C; Le Gouill S; Cortelazzo S; Rule S; Hess G; Zaja F; Vitolo U; Szymczyk M; Walewski J; Ribrag V; Unterhalt M; Hermine O; Hoster E;
Leuk Lymphoma; 2011 Dec; 52(12):2226-36. PubMed ID: 21851218
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
